A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile Infection

Trial Profile

A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile Infection

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs RBX 2660 (Primary)
  • Indications Clostridium infections
  • Focus Registrational; Therapeutic Use
  • Acronyms PUNCHCD3
  • Sponsors Rebiotix
  • Most Recent Events

    • 07 Aug 2017 According to Rebiotix media release,first patient has been enrolled.
    • 07 Aug 2017 According to Rebiotix media release,this trial is designed to support a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA).
    • 07 Aug 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top